Post hoc analysis of two phase 3 trials in active RA and PsA: in RA patients with attenuated inflammation, upadacitinib improved pain more than adalimumab or placebo at week 12, with similar results by week 26; in PsA it beat placebo and was similar to adalimumab.
Secondary analysis
Taylor et al. Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies